Medtronic: Broader Growth, Attractive Valuation (NYSE:MDT)

seekingalpha.com · 2026-10-28

Medtronic is rated Buy, trading at a 20.8% P/E discount to the sector median, with new products driving broader growth post-MiniMed separation. Learn more about MDT stock here.

TickrTrends take: Medtronic operates in the Healthcare sector and currently trades at a valuation that TickrTrends assesses as fairly valued. A valuation-focused reader should monitor whether the company's broader growth initiatives translate into earnings expansion that either justifies the current valuation or creates upside potential. Any changes in execution on growth initiatives could shift the valuation assessment if they materially impact the company's future profit generation relative to its current market price.

Read the full story at seekingalpha.com →